Growth Hormone's Role in Bone Development
Author Information
Author(s): Courtland Hayden-William, Sun Hui, Beth-On Mordechay, Wu Yingjie, Elis Sebastien, Rosen Clifford J, Yakar Shoshana
Primary Institution: Mount Sinai School of Medicine
Hypothesis
Does growth hormone (GH) influence skeletal development independently of insulin-like growth factor 1 (IGF-1) production in the liver?
Conclusion
The study found that inhibiting GH action during puberty significantly reduces body weight, femur length, and bone tissue in both control and IGF-1 deficient mice.
Supporting Evidence
- Pegvisomant treatment led to significant reductions in body weight and femur length.
- Both control and LID mice showed decreased cortical bone traits after pegvisomant treatment.
- Mechanical testing confirmed that pegvisomant treatment reduced femur stiffness and maximum load.
Takeaway
This study shows that growth hormone helps bones grow, even when another important growth factor is low. If you block growth hormone, bones can become weak.
Methodology
Male liver-specific IGF-1-deficient and control mice were treated with a growth hormone antagonist pegvisomant to assess skeletal development.
Limitations
The study primarily focused on male mice, which may limit the generalizability of the findings to females.
Participant Demographics
Male liver-specific IGF-1-deficient (LID) and control mice.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website